Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Leases: 2019-2025

Historic Operating Leases for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $2.5 million.

  • Catalyst Pharmaceuticals' Operating Leases fell 14.81% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 14.81%. This contributed to the annual value of $2.8 million for FY2024, which is 12.61% down from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Operating Leases stood at $2.5 million, which was down 4.32% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Operating Leases peaked at $4.3 million during Q1 2021, and registered a low of $2.5 million during Q3 2025.
  • For the 3-year period, Catalyst Pharmaceuticals' Operating Leases averaged around $3.1 million, with its median value being $3.0 million (2024).
  • In the last 5 years, Catalyst Pharmaceuticals' Operating Leases soared by 3,610.62% in 2021 and then fell by 22.69% in 2025.
  • Catalyst Pharmaceuticals' Operating Leases (Quarterly) stood at $4.2 million in 2021, then dropped by 7.33% to $3.9 million in 2022, then fell by 18.13% to $3.2 million in 2023, then decreased by 12.61% to $2.8 million in 2024, then fell by 14.81% to $2.5 million in 2025.
  • Its Operating Leases stands at $2.5 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.7 million for Q1 2025.